



# Medical Coverage Policy

Effective Date .....5/15/2024

Next Review Date .....4/15/2025

Coverage Policy Number..... 0355

## Liver and Liver-Kidney Transplantation

### Table of Contents

- Overview ..... 2
- Coverage Policy ..... 2
- Health Equity Considerations..... 3
- General Background..... 4
- Medicare Coverage Determinations ..... 22
- Coding Information ..... 22
- References..... 23
- Revision Details ..... 29

### Related Coverage Resources

- [Kidney Transplantation, Pancreas-Kidney Transplantation, and Pancreas Transplantation Alone](#)
- [Intestinal and Multivisceral Transplantation Donor Charges](#)

### INSTRUCTIONS FOR USE

*The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment where appropriate and have discretion in making individual coverage determinations. Where coverage for care or services does not depend on specific circumstances, reimbursement will only be provided if a requested service(s) is submitted in accordance with the relevant criteria outlined in the applicable Coverage Policy, including covered diagnosis and/or procedure code(s). Reimbursement is not allowed for services when billed for conditions or diagnoses that are not covered under this Coverage Policy (see "Coding Information" below). When billing, providers must use the most appropriate codes as of the effective date of the submission. Claims submitted for services that are not accompanied by covered code(s) under the applicable Coverage Policy*

*will be denied as not covered. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.*

## Overview

This Coverage Policy addresses liver transplantation and simultaneous liver-kidney (SLK) transplantation.

## Coverage Policy

**Liver transplantation is considered medically necessary for an individual with ANY of the following indications:**

- end-stage liver failure
- hepatocellular carcinoma and BOTH of the following criteria are met:
  - (one class 5 lesion greater than or equal to 2 cm and less than or equal to 5 cm in size, or two or three class 5 lesions each greater than or equal to 1 cm and less than or equal to 3 cm in size)
  - alpha-fetoprotein (AFP) level  $\leq$  1000 ng/mL
- hepatoblastoma which is confined to the liver
- metabolic disease with intact hepatic synthetic function (e.g., type I hyperoxaluria, familial homozygous hypercholesterolemia, familial amyloidosis)
- unresectable perihilar or hilar cholangiocarcinoma with ALL of the following:
  - measures  $\leq$ 3cm in radial diameter
  - absence of intrahepatic or extrahepatic metastasis,
  - without nodal disease
- neuroendocrine/gastroenteropancreatic (GEP) tumors with ALL of the following:
  - unresectable liver metastasis
  - prior complete resection of the primary GEP
  - absence of extrahepatic metastasis
  - failure to respond to medical and/or interventional treatment
  - severe hypoglycemia, poorly controlled hyperglycemia, cardiac distress, respiratory distress or other symptoms directly attributable to aberrant GEP tumor production of life-threatening hormones such as insulin, catecholamines, or histamine

**Liver retransplantation is considered medically necessary for an individual considered to have a significant chance of success and who still meet eligibility criteria for primary transplantation for ANY of the following indications:**

- primary graft failure
- hepatic artery thrombosis
- severe rejection
- recurrence of the disease which prompted the initial liver transplantation

**Simultaneous liver-kidney (SLK) transplantation is considered medically necessary for an individual 18 years or older who meets medical necessity criteria for liver transplantation with ANY of the following indications:**

- chronic kidney disease (CKD) with a measured or calculated glomerular filtration rate (GFR)  $\leq 60$  mL/min for more than 90 consecutive days and ANY of the following:
  - receiving regularly administered dialysis as an end-stage renal disease (ESRD) patient in a hospital based, independent non-hospital based, or home setting
  - at the time of registration on the kidney waiting list, the individual's most recent measured or calculated creatinine clearance (CrCl) or GFR is  $\leq 30$  mL/min
  - on a date after registration on the kidney waiting list, the individual's measured or calculated CrCl or GFR is  $\leq 30$  mL/min
- sustained acute kidney injury and at least ONE of the following for the previous 6 weeks:
  - receiving dialysis at least once every 7 days
  - individual has a measured or calculated CrCl or GFR that is consistently  $\leq 25$  mL/min
- a diagnosis of ANY of the following:
  - hyperoxaluria
  - atypical hemolytic uremic syndrome (HUS) from mutations in factor H or factor I
  - familial non-neuropathic systemic amyloidosis
  - methylmalonic aciduria

**Liver transplantation is considered not medically necessary for an individual with ANY of the following contraindications to transplant surgery:**

- ongoing alcohol abuse
- active extrahepatic malignancy that is expected to significantly limit future survival
- colorectal cancer metastatic to the liver
- known intrahepatic or central cholangiocarcinoma
- persistent, recurrent or unsuccessfully treated major or systemic infections
- systemic illness or comorbidities that would be expected to substantially negatively impact the successful completion and/or outcome of transplant surgery
- a pattern of demonstrated noncompliance which would place a transplanted organ at serious risk of failure
- human immunodeficiency virus (HIV) disease unless ALL of the following are noted:
  - cluster determinant (CD)4 count  $>100$  cells/mm<sup>3</sup>
  - HIV-1 ribonucleic acid (RNA) undetectable
  - stable antiretroviral therapy for more than three months
  - absence of serious complications associated with HIV disease (e.g., opportunistic infection, including aspergillus, tuberculosis, coccidioidomycosis; or resistant fungal infections; or Kaposi's sarcoma or other neoplasm)
- donor with:
  - ongoing alcohol abuse
  - active malignancy, with the exception of non-melanotic skin cancer
  - persistent, recurrent or unsuccessfully treated infections, including hepatitis A, B or C or HIV
  - active systemic illness or serious comorbidities that would be expected to substantially negatively impact the successful completion and/or outcome of transplant surgery
  - active systemic illness that is likely to negatively affect survival

**The use of a mechanical preservation machine for liver transplantation is considered not medically necessary.**

## Health Equity Considerations

In 2021, 9,234 liver transplants (adult and pediatric) were performed in the United States. The recipients were 61.7% male, 69.5% White, 16.7% Hispanic, 7.6% Black, and 4.4% Asian.

Disparities exist in referral and access to the liver transplant (LT) waitlist, and social determinants of health (SDOH) such as income, lack of private insurance and education are increasingly recognized as important factors driving health inequities, including in liver and liver-kidney transplantation. These disparities manifest in the field of liver transplantation via differences in waitlist mortality, transplantation rate, and outcomes after transplantation.

There are marked differences in LT transplantation rates based on patient race and biological sex. Compared to males, females are less likely to receive liver transplant. An individual with Black or Native American ethnicity is less likely to receive liver transplant compared to whites; while an individual of Asian or Hispanic ethnicity is more likely to receive liver transplant (Mansour et al., 2022; Yilam et al., 2023).

Studies suggest that socioeconomic factors at time of transplant may also impact long-term post-transplant survival. Lower socioeconomic status and minority race and ethnicity have been associated with poorer health outcomes, likely related to unequal distribution of and access to healthcare resources. In some studies, documentation status, unstable housing, unemployment and having public insurance increased the risk of waitlisting and waitlist removal and mortality and negatively influenced post-LT patient survival and graft. Lack of college education also proved to have a detrimental impact on both patient survival and graft survival (Haug et al., 2021; Yilam et al., 2023).

## General Background

Liver transplantation (LT) is a complex operation requiring vascular reconstruction of the hepatic artery, the portal vein, and the hepatic venous system. Surgical techniques, which continue to evolve, include the orthotopic approach, involving replacement of the recipient liver with the donor liver, and the heterotopic approach in which the recipient liver is left in place and the donor liver is transplanted to an ectopic site. The whole liver, a reduced liver, or a liver segment may be transplanted depending on whether the donor is cadaveric (deceased) or living.

Living-donor liver transplantation was introduced as an alternative to deceased donor transplantation in response to the shortage of available cadaveric donor organs and is used for both adults and children. The graft from a living donor is more commonly from a relative of the recipient. The success of this type of transplantation is based on the ability of the liver to regenerate in both the donor and the recipient. The graft must be of adequate size in order to function in the recipient. The risks and benefits of using a living-donor graft must be considered as there are surgical risks to both the recipient and the donor. Benefits to the recipient include a reduced chance of mortality related to waiting for a cadaveric-donor organ, a reduced likelihood of primary non-function of the graft, and a potential decrease in the chance of graft rejection and the need for immunosuppression. Ethical concerns regarding living donor liver transplantation (LDLT) are related to the potential for donor morbidity and mortality. Opponents argue that it is unacceptable to place a healthy donor at risk of long-term debility or death. Donation of the left lateral segment or left lobe, used primarily in pediatric transplantation, is associated with a 5 to 10 percent chance of surgical complications and a mortality rate of less than 1 percent. The estimated mortality for right lobe donation, used in adult-to-adult LDLT, is around 0.5 percent.

In 2021, 9,234 liver transplants (adult and pediatric) were performed in the United States, of which 8,665 (93.8%) were from deceased donors and 569 (6.2%) were from living donors. The recipients were 61.7% male, 69.5% White, 16.7% Hispanic, 7.6% Black, and 4.4% Asian. The

largest age group was adults aged 50-64 years, with a growing proportion of patients aged 35-49 years and no increase in the group aged 65 years or older in the past year. Alcohol-associated liver disease was again the most common indication for liver transplant overall.

There were 780 simultaneous liver-kidney transplants in 2021 (adult and pediatric), representing 8.4% of liver transplant recipients during the calendar year. This proportion has been stable over the past several years and decreased from a peak of 9.4% in 2016, just prior to the introduction of standardized medical eligibility criteria for simultaneous liver-kidney transplant in 2017 (Scientific Registry of Transplant Recipients [SRTR]).

### **Indications for Liver Transplantation**

The major indications for liver transplantation are irreversible hepatic failure or liver cancer. Each liver transplant candidate is assigned a score that reflects the probability of death within a 3-month period as determined by the Model for End-Stage Liver Disease (MELD) scoring system or the Pediatric End Stage Liver Disease (PELD) scoring system. Liver candidates can also be assigned a priority status if the candidate meets the requirements for that status. The Liver and Intestinal Organ Transplantation Committee establishes guidelines for review of status and MELD or PELD score exception requests. If a candidate's transplant program believes that a candidate's current MELD or PELD score does not appropriately reflect the candidate's medical urgency for transplant, the transplant program may submit a MELD or PELD score exception request to the National Liver Review Board (NLRB).

A liver distribution system based on acuity circles went into effect in February 2020. Since implementation of this policy change, waiting times have decreased for patients with a MELD score of  $\geq 29$ , while waiting times have increased for those patients with a MELD score of  $\leq 28$ . This has placed pressure on transplant programs to increasingly pursue DCD and other "marginal" livers for patients listed with a MELD score of  $\leq 28$ . HCC patients no longer have a "ladder" model of increasing exception scores over time. This has significantly reduced access to standard criteria livers for patients with HCC. As a result, the utilization of DCD livers for patients with HCC has significantly increased (Croome, et al., 2023).

### **Contraindications to Liver Transplantation**

Many factors affect the outcome of solid organ transplantation. Prior to transplantation a rigorous assessment of the recipient's medical status should be conducted to confirm that transplantation constitutes the best option for managing the patient's disease and that no contraindications exist. According to the American Association for the Study of Liver Diseases (AASLD) and the American Society of Transplantation (Martin, et al., 2014), these are listed contraindications to liver transplant:

- MELD Score  $< 15$
- Severe cardiac or pulmonary disease
- AIDS
- Ongoing alcohol or illicit substance abuse
- Hepatocellular carcinoma with metastatic spread
- Uncontrolled sepsis
- Anatomic abnormality that precludes liver transplantation
- Intrahepatic Cholangiocarcinoma
- Extrahepatic malignancy
- Fulminant hepatic failure with sustained intracranial pressure  $> 50$  mm Hg or cerebral perfusion pressure  $< 40$  mm Hg\*
- Hemangiosarcoma
- Persistent noncompliance
- Lack of adequate social support system

### **Colorectal Liver Metastases (CRLM)**

Currently, liver transplantation for individuals with colorectal cancer metastatic to the liver is being investigated. From December 2017 to March 2022, 46 patients received LT for nonresectable CRLM in 15 centers in the US. Of 46 patients who underwent LT for CRLM, 26 patients (56.5%) received LTs using living donor LT (LDLT), and 20 patients received LT using deceased donor (DDLT) (43.5%). The 1-, 2-, and 3-year, disease-free, survival rates were 75.1, 53.7, and 53.7% (Sasaki, et al., 2023).

UNOS/OPTN criteria for liver allocation does not address colorectal liver metastases. It does not OPTN does not provide MELD exception points for this diagnosis. UNOS/OPTN criteria for liver allocation does specifically address other cancers such as hepatocellular carcinoma (HCC). The NCCN Guidelines for both Colon cancer and Rectal cancer do not address liver transplant.

There are clinical trials being conducted that address the use of LT for colorectal liver metastases (CRLM). Preliminary studies report that some carefully selected patients may benefit from LT compared to current treatment options (Dueland, et al., 2020 [SECA II]; Smedman, et al., 2020 [SECA D arm]; Hagness, et al., 2013 [SECA I]). There are minimal prospective data and LT remains exploratory in the setting of CRLM. Additionally, several challenges remain including but not limited to defining appropriate selection criteria for these patients. Further evidence from ongoing and future well-designed trials are needed to determine if and to what extent there is a role for LT in liver-limited surgically unresectable colorectal liver metastases.

In 2016, SECA III (NCT03494946) and TRANSMET (Liver Transplantation in Patients with Unresectable Colorectal Liver Metastases Treated by Chemotherapy) (NCT0259748) began enrolling into phase III RCTs. TRANSMET was the first clinical trial outside of Norway. Three additional trials have opened, SOULMATE (The Swedish Study of Liver Transplantation for Nonresectable Colorectal Cancer Metastases) (NCT04161092) in Sweden, COLT (Improving Outcome of Selected Patients with Non-resectable Hepatic Metastases from Colorectal Cancer With Liver Transplantation) (NCT03803436) in Italy, and TRASMETIR (Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases) (NCT04616495) in Spain. All except for COLT, are phase III RCT with participants randomized to LT or standard of care. The COLT trial is a phase II study comparing outcomes of LT to a COLT-eligible matched cohort in another open phase III trial for chemotherapy with anti-epidermal growth factor receptor (EGFR) (Robinson, et al., 2024; Schepers, et al., 2024; Lebeck Lee, et al., 2022).

### **Human Immunodeficiency Virus (HIV)**

Historically, HIV positivity has been considered a contraindication to solid organ transplantation. Access to liver transplantation was limited due to questions regarding life expectancy, clinical efficacy, and complications post-liver transplantation caused by interactions between antiviral therapy and immunosuppressive medications, and the increased risk of opportunistic infections.

More recently liver transplantation has become an acceptable treatment option for selected individuals who are HIV-positive. While overall survival is generally lower for individuals with HIV-infection compared to HIV-negative persons, mono-infection (i.e. HIV infection only) does not seem to be a significant risk factor for survival after liver transplantation. Orthotopic liver transplantation appears to be a safe therapeutic option in the short term for selected persons with HIV infection who have end-stage liver disease.

At present, AASLD criteria for liver transplantation include a CD 4 count  $>100/\mu\text{L}$  with a viral load anticipated to be completely suppressed at time of transplant (Martin, et al., 2014).

### **Donor Health**

The health of the donor is also an important factor in liver transplantation outcomes. Hepatitis C virus (HCV) infection in the donor can affect the health of the donor liver, making individuals with persistent, recurrent, or untreated HCV infection unacceptable donors. Likewise, donor candidates who are hepatitis B surface antigen- (HbsAg) positive are also generally excluded from living-donor liver transplant donation to prevent transmission of disease to recipients. Factors which may negatively affect recipient outcomes after liver transplantation including ongoing alcohol abuse, active systemic illness, and malignancy, are also considered contraindications to donation.

### **Retransplantation of the Liver**

Retransplantation may be appropriate for carefully selected patients experiencing graft loss if an improvement in survival is expected; however, liver retransplantation should be used with discretion in the emergency setting and avoided in patients with little chance of success. In adults, the most common condition resulting in the need for retransplantation of the liver is recurrent infection with hepatitis C virus (HCV). Retransplantation in patients with HCV is controversial due to concerns of aggressive disease recurrence post retransplantation, and decreased patient and graft survival. Several retrospective cohort studies have examined the outcomes of patients retransplanted for recurrent HCV demonstrating lower patient and graft survival in some studies.

### **Simultaneous Liver-Kidney (SLK) transplantation**

Since the introduction of the model for end-stage disease (MELD) score in 2002, there has been an increased use of SLK transplantation. Of all adult liver transplants in the US in 2019, 787 (9.4%) were multi-organ, most of which were simultaneous liver-kidney (SLK) transplants (704, compared with 347 in 2009). The reasons for this increase are multifactorial. First, allocation using the MELD score prioritizes patients with renal dysfunction, as the score incorporates both serum creatinine (Scr) and utilization of pretransplant renal replacement therapy (RRT). Second, superior outcomes have been observed following SLK in recipients with advanced pretransplant renal dysfunction. Finally, there has been a steady increase in the incidence of nonalcoholic fatty liver disease, resulting in more patients on the LT waiting list with this diagnosis (Bari, et al., 2021; Pita, et al., 2019; Singal, et al., 2019; Miles, et al., 2018).

Goyes et al. (2020) evaluated post-graft survival outcomes following Simultaneous Liver-Kidney Transplant (SLKT) following adoption of updated criteria in 2017. The UNOS OPTN database was used to identify Caucasian, African American (AA), and Hispanic patients who underwent SLKT from August 10, 2017 to December 31, 2019. Children (age < 18 years), patients listed as status 1, and living donor transplants were excluded.

- Hispanics presented more severe disease and had a higher MELD score at transplant than Caucasian and AA patients.
- Patients with non-alcoholic steatohepatitis (NASH) and alcohol-related liver disease (ALD) formed a larger proportion of the subjects undergoing SLKT in both Caucasians and Hispanics, while hepatitis C virus (HCV) was the most common disease present in AAs.
- There was no difference between racial/ethnic groups in post-transplant graft survival at six months, one year, and two years ( $p = 0.905$ ).
- On multivariate Cox regression analysis, being male, cold ischemia, alcohol-related liver disease (ALD), and hepatitis C virus (HCV) were associated with a higher risk of graft failure.

Jay et al. (2020) retrospectively analyzed UNOS data for adult liver transplant recipients between January 1, 2002 and December 31, 2018. The aim was to compare survival following simultaneous liver-kidney transplantation (SLK), early kidney after liver transplantation (KALT), and liver transplantation alone (LTA) in adult patients. Early KALT was defined as 60 to 365 days between liver and subsequent kidney transplantation (reflecting safety net listing criteria). There were 6,774 SLK, 120 KALT at 60 to 365 days, and 11,501 LTA. Early KALT had equivalent survival compared with SLK, both for all KALT (hazard ratio [HR] 0.58,  $p=0.05$ ) and for deceased donor

(DD) KALT only (HR 0.72, p=0.32). Simultaneous liver-kidney transplantation was associated with improved survival compared with LTA (HR 0.82, p < 0.01). Early KALT was associated with a greater reduction in mortality compared with LTA, but this was not significant (HR 0.58, p=0.05). The authors concluded that early KALT has equivalent survival compared with SLK transplantation, both for all KALT and for DD KALT only, supporting the promise of the “safety net.”

## Professional Societies/Organizations

**Organ Procurement & Transplantation Network (OPTN):** The OPTN Policies document (OPTN, 3/19/2024) addresses Allocation of Livers and Liver-Intestines in Policy 9. Sections within the Policy address many topics related to liver transplant including Requirements for Hepatocellular Carcinoma (HCC) MELD or PELD Score Exceptions.

### OPTN Policy 9.5.I.ii Eligible Candidates Definition of T2 Lesions

Candidates with T2 HCC lesions are eligible for a standardized MELD or PELD exception if they have an alpha-fetoprotein (AFP) level less than or equal to 1000 ng/mL. T2 stage is defined as candidates with either of the following:

- One class 5 lesion greater than or equal to 2 cm and less than or equal to 5 cm in size.
- Two or three class 5 lesions each greater than or equal to 1 cm and less than or equal to 3 cm in size.

A candidate who has previously had an AFP level greater than 1000 ng/mL at any time must qualify for a standardized MELD or PELD exception according to Policy 9.5.I.iv: Candidates with Alpha-fetoprotein (AFP) Levels Greater than 1000.

### OPTN Policy 9.5.I.iii Lesions Eligible for Downstaging Protocols

Candidates are eligible for a standardized MELD or PELD exception if, before completing local-regional therapy, they have lesions that meet *one* of the following criteria:

- One class 5 lesion greater than 5 cm and less than or equal to 8 cm
- Two or three class 5 lesions that meet all of the following:
  - at least one lesion greater than 3 cm
  - each lesion less than or equal to 5 cm, and
  - a total diameter of all lesions less than or equal to 8 cm
- Four or five class 5 lesions each less than 3 cm, and a total diameter of all lesions less than or equal to 8 cm

For candidates who meet the downstaging criteria above and then complete local-regional therapy, their viable lesions must subsequently meet the requirements for T2 stage according to Policy 9.5.I.ii: Eligible Candidates Definition of T2 Lesions to be eligible for a standardized MELD or PELD exception. Downstaging to meet eligibility requirements for T2 stage must be demonstrated by dynamic-contrast enhanced CT or MRI performed after local-regional therapy. Candidates with lesions that do not initially meet the downstaging protocol inclusion criteria who are later downstaged and then meet eligibility for T2 stage are not automatically eligible for a standardized MELD or PELD exception and must be referred to the NLRB for consideration of a MELD or PELD exception.

### OPTN Policy 9.5.I.iv Candidates with Alpha-fetoprotein (AFP) Levels Greater than 1000

Candidates with lesions meeting T2 stage according to Policy 9.5.I.ii Eligible Candidates Definition of T2 Lesions but with an alpha-fetoprotein (AFP) level greater than 1000 ng/mL may be treated with local-regional therapy. If the candidate’s AFP level falls below 500 ng/mL after treatment, the candidate is eligible for a standardized MELD or PELD exception



as long as the candidate's AFP level remains below 500 ng/mL. Candidates with an AFP level greater than or equal to 500 ng/mL following local-regional therapy at any time must be referred to the NLRB for consideration of a MELD or PELD exception.

OPTN Table 9-17: Medical Eligibility Criteria for Liver-Kidney Allocation (2/01/2023) OPTN Policy)

If the candidate's transplant nephrologist confirms a diagnosis of:	Then the transplant program must report to the OPTN and document in the candidate's medical record:
Chronic kidney disease (CKD) with a measured or calculated glomerular filtration rate (GFR) less than or equal to 60 mL/min for greater than 90 consecutive days	<p>At least <i>one</i> of the following:</p> <ul style="list-style-type: none"> <li>• That the candidate has begun regularly administered dialysis as an end-stage renal disease (ESRD) patient in a hospital based, independent non-hospital based, or home setting.</li> <li>• At the time of registration on the kidney waiting list, that the candidate's most recent measured or calculated creatinine clearance (CrCl) or GFR is less than or equal to 30 mL/min.</li> <li>• On a date after registration on the kidney waiting list, that the candidate's measured or calculated CrCl or GFR is less than or equal to 30 mL/min.</li> </ul>
Sustained acute kidney injury	<p>At least <i>one</i> of the following, or a combination of <i>both</i> of the following, for the last 6 weeks:</p> <ul style="list-style-type: none"> <li>• That the candidate has been on dialysis at least once every 7 days.</li> <li>• That the candidate has a measured or calculated CrCl or GFR less than or equal to 25 mL/min at least once every 7 days.</li> </ul> <p>If the candidate's eligibility is not confirmed at least once every seven days for the last 6 weeks, the candidate is not eligible to receive a liver and a kidney from the same donor.</p>
Metabolic disease	<p>A diagnosis of at least <i>one</i> of the following:</p> <ul style="list-style-type: none"> <li>• Hyperoxaluria</li> <li>• Atypical hemolytic uremic syndrome (HUS) from mutations in factor H or factor I</li> <li>• Familial non-neuropathic systemic amyloidosis</li> <li>• Methylmalonic aciduria</li> </ul>

**National Comprehensive Cancer Network Guidelines™ (NCCN Guidelines™):** The NCCN Guidelines (Version 2.2023 — September 14, 2023) for Hepatobiliary Cancers address liver transplantation as follows:

Principles of Surgery:

Patients meeting the UNOS criteria (AFP level ≤1000 ng/ml and single lesion ≥2 cm and ≤5cm, or 2 or 3 lesions ≥1 cm and ≤3cm) should be considered for transplantation (cadaveric or living donation). There are patients whose tumor characteristics are marginally outside of the UNOS guidelines who should be considered for transplant. Furthermore, there are patients who are downstaged to within criteria that can also be considered for transplantation. Candidates are eligible for a standardized MELD exception

if, before completing loco regional therapy, they have lesions that meet one of the following criteria:

- One lesions > 5cm and ≤ 8 cm
- Two or three lesions that meet all of the following: each lesion ≤ 5 cm with at least one lesion > 3cm and a total diameter of all lesions ≤ 8 cm
- Four or five lesions each < 3 cm and a total diameter of all lesions ≤ 8 cm

Patients with Child-Pugh Class A function, who fit UNOS criteria and are resectable, could be considered for resection or transplant. There is controversy over which initial strategy is preferable to treat such patients (NCCN, page HCC-D).

The NCCN Guidelines (Version 3.2023 — November 8, 2023) for Biliary Tract Cancers addresses liver transplantation as follows:

Extrahepatic cholangiocarcinoma /Presentation and Workup /Primary Treatment: Unresectable perihilar or hilar cholangiocarcinoma that measures ≤3cm in radial diameter, with the absence of intrahepatic or extrahepatic metastasis, and without nodal disease, as well as those with primary sclerosing cholangitis may be considered for liver transplantation at a transplant center that has an UNOS-approved protocol for transplantation of cholangiocarcinoma (NCCN, page EXTRA-1).

The NCCN Guidelines (Version 1.2024 — January 29, 2024) for Colon Cancer does not address liver transplant. Hepatic resection is the treatment of choice for resectable liver metastases from CRC. When hepatic metastatic disease is not optimally resectable based on insufficient remnant liver volume, approaches using preoperative portal vein embolization, staged liver resection, or yttrium-90 radioembolization can be considered (page COL-C).

The NCCN Guidelines (Version 1.2024 — January 29, 2024) for Rectal Cancer does not address liver transplant. Hepatic resection is the treatment of choice for resectable liver metastases from CRC. When hepatic metastatic disease is not optimally resectable based on insufficient remnant liver volume, approaches using preoperative portal vein embolization or staged liver resections can be considered (page REC-C).

**American Association for the Study of Liver Disease (AASLD)/ American Society of Transplantation (AST):** The AASLD and AST have published numerous joint guidelines, including some specific to liver transplantation.

Evaluation for Liver Transplantation in Adults: 2013 Practice Guideline by the AASLD and the American Society of Transplantation (Marin, et al., 2014) states liver transplantation (LT) is indicated for severe acute or advanced chronic liver disease when the limits of medical therapy have been reached. Recognition of cirrhosis per se does not imply a need for LT. Many patients with cirrhosis in the absence of an index complication such as ascites or variceal hemorrhage will not develop hepatic decompensation, although patients with cirrhosis have diminished survival compared to the population as a whole. Acute liver failure complications of cirrhosis include ascites, chronic gastrointestinal blood loss due to portal hypertensive gastropathy, encephalopathy, liver cancer, refractory variceal hemorrhage and synthetic dysfunction.

Evaluation of the Pediatric Patient for Liver Transplantation: 2014 Practice Guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (Squires, et al., 2014) indications for LT include biliary atresia (32%), metabolic/genetic conditions (22%), acute liver failure (11%), cirrhosis (9%), liver tumor (9%), immune-mediated liver and biliary injury (4%), and other miscellaneous conditions (13%). Within these broad categories rest many rare conditions with myriad presentations.

**American Society of Transplantation (AST):** The AST has several Key Position Statements, including but not limited to Deceased Organ Donation, Insurance Coverage for Living Donors, and Insurance Coverage for Transplant Recipients, and Living Organ Donation. They also publish guidelines, including Long-Term Medical Management of the Pediatric Patient after Liver Transplantation, Long-Term Management of the Successful Adult Liver Transplant, Curricular Guidelines for Training in Transplant Hepatology, and a Position paper on Indications for pediatric intestinal transplantation.

**Kidney Disease: Improving Global Outcomes (KDIGO):** The KDIGO 2020 Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation guideline included recommendations regarding liver-kidney transplantation:

- Hyperoxaluria (oxalosis), primary and secondary 9.16.1: We suggest that candidates with primary hyperoxaluria type 1 be considered for combined or sequential liver-kidney transplantation (2C).
- Hepatitis C virus (HCV) 10.5.2.4.2: We recommend referring patients with HCV and decompensated cirrhosis for combined liver-kidney transplantation (1B) and deferring HCV treatment until after transplantation (1D).
- Liver disease 16.7.3: We recommend that candidates with cirrhosis or suspected cirrhosis be referred to a specialist with expertise in combined liver-kidney transplantation for evaluation (1B).

Description for grading recommendations:

Level 1: "We recommend". Most patients should receive the recommended course of action.

Level 2: "We suggest". Different choices will be appropriate for different patients. Each patient needs help to arrive at a management decision consistent with her or his values and preferences.

A: High Quality of Evidence. We are confident that the true effect lies close to that of the estimate of the effect.

B: Moderate Quality of Evidence. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

C: Low Quality of Evidence. The true effect may be substantially different from the estimate of the effect.

D: Very low Quality of Evidence. The estimate of effect is very uncertain, and often will be far from the truth (Chadban, et al., 2020).

**International Hepato-Pancreato-Biliary Association:** The International Hepato-Pancreato-Biliary Association published Consensus Guidelines on Liver transplantation for non-resectable colorectal liver metastases (Bonney, et al., 2021). The purpose was to standardize nomenclature and define management principles in five key domains: patient selection, evaluation of biological behavior, graft selection, recipient considerations, and outcomes. The final consensus document includes 44 statements, standardized nomenclature, and a practical management algorithm.

**International Liver Transplantation Society (ILTS):** The Working Group Report From the ILTS Transplant Oncology Consensus Conference (Hibi, et al., 2020) titled 'Liver Transplantation for Colorectal and Neuroendocrine Liver Metastases and Hepatoblastoma' published these Recommendations regarding CRLM:

1. LT can be a viable option in highly selected patients with unresectable CRLM with only liver involvement (moderate level of evidence and moderate recommendation).
2. LT for CRLM with low Oslo score  $\leq 2$  (maximum tumor diameter  $\leq 5.5$  cm, pretransplant carcinoembryonic antigen  $\leq 80$   $\mu\text{g/L}$ , response to chemotherapy, time interval: diagnosis to

LT  $\geq$  2 y) may improve the 5-year overall survival rates over those achieved with the current standard of care (moderate level of evidence and moderate recommendation).

3. Minimization of immunosuppression is recommended (low level of evidence and moderate recommendation).
4. Aggressive treatment of all posttransplant resectable recurrences is recommended (low level of evidence and moderate recommendation).
5. There is a need for an international registry to coordinate data collection and design further studies on LT for CRLM (moderate level of evidence and moderate recommendation).

The document also addressed neuroendocrine liver metastases and hepatoblastoma.

## **Mechanical Preservation Machines**

Static cold storage (SCS): Cold flush preservation solutions, known as static cold storage (SCS) represents the current gold standard. In SCS, the liver is perfused with several liters of 4 degrees Celsius cold preservation fluid through the portal vein and hepatic artery before being packed and placed on ice for transport. Several solutions have been developed for this purpose. The benefits of SCS compared with allograft preservation solely by placement on ice are its abilities to cool the organ from its core to maintain cellular viability and to decrease cellular swelling and rupture.

Hypothermic machine perfusion (HMP): HMP is an umbrella term for various forms of machine perfusion (MP) that use hypothermic perfusion as their smallest common denominator. Systems that provide hypothermic oxygenated perfusion are termed hypothermic oxygenated perfusion (HOPE) if the perfusate is delivered via the portal vein and dual hypothermic oxygenated perfusion (D-HOPE) if the perfusate is additionally delivered through the hepatic artery.

Normothermic machine perfusion (NMP): NMP entails the perfusion of a liver graft under normal body temperature with oxygenated packed red blood cells suspended in a colloid solution, nutrients, and medication, allowing the organ to maintain function under simulated physiological conditions. A main argument in favor of NMP is that it allows for the measurement of objective parameters related to graft function and the identification of transplantable marginal organs that otherwise would have been discarded. The identification and definition of the relevant parameters and their cut-offs are ongoing, conversely, a combination of different perfusion methods has been attempted in the past, such as D-HOPE, controlled oxygenated rewarming, and NMP, but their roles and usefulness require further clarification (Staubli, et al., 2023).

Machine perfusion technique which is applied in the donor before the organs are removed is termed normothermic regional perfusion (NRP).

## **Mechanical Preservation Machine - U.S. Food and Drug Administration (FDA)**

Currently there are two ex situ mechanical preservation machines that are FDA approved for clinical use, both are normothermic. Currently there are no hypothermic devices that are FDA approved for clinical use in the USA.

The TransMedics® Organ Care System (OCS™) Liver received FDA PMA approval September 28, 2021 (P200031) (TransMedics, Inc., Andover, Massachusetts). The OCS Liver is a portable platform designed to maintain donor livers in a near-physiologic, normothermic, and perfused state. The OCS Liver is comprised of three major components: 1) OCS Liver Console; 2) OCS Liver Perfusion Module and Accessories (Perfusion Set [LvPS]); 3) OCS Liver Bile Salts Set.

- Indications for Use are stated as: "the TransMedics® Organ Care System (OCS™) Liver is a portable extracorporeal liver perfusion and monitoring system indicated for preservation and monitoring of hemodynamics and metabolic function which allows for ex-vivo assessment of liver allografts from donors after brain death (DBD) or liver allografts from

donors after circulatory death (DCD)  $\leq 55$  years old and with  $\leq 30$  mins of warm ischemic time, macrosteatosis  $\leq 15\%$ , in a near-physiologic, normothermic and functioning state intended for a potential transplant recipient.”

The OrganOx metra<sup>®</sup> System received FDA PMA approval December 9, 2021 (P200035) (OrganOx, Limited; Oxford UK). The OrganOx metra is a fully automated normothermic machine perfusion (NMP) device for the preservation and transport of donor livers destined for transplantation. It is designed to transport and preserve donor livers prior to transplantation and includes three main components: 1) a reusable base unit that contains software, hardware, and a trolley or hardcover; 2) a sterilized, single use, disposable fluid management circuit; and 3) the solutions required for perfusion.

- Indications for Use are stated as: “the OrganOx metra<sup>®</sup> is a transportable device intended to be used to sustain donor livers destined for transplantation in a functioning state for a total preservation time of up to 12 hours. The OrganOx metra<sup>®</sup> device is suitable for liver grafts from donors after brain death (DBD), or liver grafts from donors after circulatory death (DCD)  $\leq 40$  years old, with  $\leq 20$  mins of functional warm ischemic time (time from donor systolic blood pressure  $< 50$  mmHg), and macrosteatosis  $\leq 15\%$ , in a near-physiologic, normothermic and functioning state intended for a potential transplant recipient.

The FDA approval was based on clinical trial NCT02775162, which has not yet been published in the peer-reviewed scientific literature.

Non-FDA Approved Systems:

Organ Recovery Systems LifePort<sup>®</sup> Liver Transporter System is pending FDA-approval at this time (hypothermic) (Panayotova, et al., 2023; PILOT<sup>™</sup> trial NCT03484455; PILOT<sup>™</sup>\_CA NCT05574361).

According to Bridge to Life, Ltd. website, Bridge to Life announced investigational device exemption (IDE) approval by the U.S. Food and Drug Administration (FDA) for its VitaSmart<sup>™</sup> Liver Machine Perfusion System on December 14, 2021. The website states The VitaSmart<sup>™</sup> Liver Machine Perfusion System “provides clinicians with the ability to implement hypothermic oxygenated perfusion (HOPE) of liver grafts in the transplant center operating room after ex-vivo cold storage prior to transplant surgery”.

According to XVIVO’s website, XVIVO (XVIVO Perfusion AB) was granted Breakthrough Device Designation from the FDA on September 20, 2022 for their Liver Assist device, “indicated for ex-vivo oxygenated machine perfusion for preservation of donor livers prior to transplantation”. XVIVO Perfusion AB (“XVIVO”) completed the acquisition of Organ Assist B.V. (“Organ Assist”) in September 2020. The website says that Liver Assist is only device for ex vivo liver perfusion at temperatures ranging from hypothermic to normothermic.

The manufacturer site says Paragonix LIVERguard<sup>™</sup> Donor Liver Preservation System “is FDA cleared”.

No mention of LIVERguard<sup>™</sup> was located on the FDA website. The manufacturer site states these are the Indications for Use:

- The Paragonix LIVERguard<sup>™</sup> Donor Liver Transport System is intended to be used for the static hypothermic preservation of liver during transportation and eventual transplantation into a recipient using cold storage solutions indicated for use with donor livers.
- The intended organ storage time for the LIVERguard<sup>™</sup> system is up to 15 hours.

- Donor livers exceeding clinically accepted static hypothermic preservation times should be evaluated by the transplant surgeon to determine transplantability in accordance with accepted clinical guidelines and in the best medical interest of the intended recipient.
- Note: A partial liver can be transported via the LIVERguard™ System by packaging liver per institutional protocol and UNOS guidelines

### **Mechanical Preservation Machine - Professional Societies/Organizations**

There are no published guidelines addressing the use of mechanical preservation machines (MPM) for liver transplants. Professional Society opinions are not organ specific.

**Organ Procurement & Transplantation Network (OPTN):** The OPTN Policies document (OPTN, 1/10/2024) addresses Mechanical Preservation Machine in Policy 16: Organ and Extra Vessel Packaging, Labeling, Shipping, and Storage. (Note that Policy 16 is not organ specific.)

#### 16.3.E.ii Mechanical Preservation Machine

Members may use a mechanical preservation machine to transport organs. A mechanical preservation machine may be reused only if it is properly cleaned and sanitized and all labels from previous donor organs are removed.

#### 16.3.E.iii Cooler

If a member of the organ recovery team is accompanying the organ to the potential transplant recipient's transplant hospital, the organs and tissue typing material may be transported in a cooler. A cooler may be reused only if it is properly cleaned and sanitized and all labels from previous donor organs are removed.

**American College of Physicians (ACP):** The ACP published a Statement of Concern (2021) titled Ethics, Determination of Death, and Organ Transplantation in Normothermic Regional Perfusion (NRP) with Controlled Donation after Circulatory Death (cDCD). It includes but is not limited to the following:

#### Conclusion and Recommendation

It is tragic when a patient dies awaiting a needed organ. But organ procurement and transplantation must satisfy ethical standards in meeting this need. NRP-cDCD raises profound ethical questions regarding the dead donor rule, fundamental ethical obligations of respect, beneficence, and justice, and the categorical imperative to never use one individual merely as a means to serve the ends of another, no matter how noble or good those ends may be.

The questions and concerns raised here have not been adequately considered to date. Further professional and public discussion of NRP-cDCD-- a protocol more accurately described as organ retrieval after cardiopulmonary arrest and the induction of brain death— is needed. ACP recommends the use of NRP-cDCD be paused. The burden of proof regarding the ethical and legal propriety of this practice has not been met. Sound ethical arguments, not just assertions, must underpin organ procurement methods and such efforts must be consistent with US legal and ethical standards for determination of death. Without this, we risk decreasing public confidence in health care and undermining support for organ donation, further exacerbating the problem this protocol seeks to address (ACP, 2021).

**American Society of Transplant Surgeons (ASTS):** The ASTS Consensus Statement on Normothermic Regional Perfusion (Wall, et al., 2024) states:

The ASTS recognizes that there are ethical considerations regarding normothermic regional Perfusion (NRP) procedures but feels strongly that NRP saves lives and offers an ethically

sound donation modality that does not violate essential moral, philosophical, or bioethical principles. NRP must be implemented in a way that maximizes the number of patient life years saved and follows the highest ethical standards. To do this, several committees will be formed to provide guidelines for the standard of care and ethical boundaries for the conduct of thoracoabdominal (TA)- and abdominal (A)-NRP.

The American Society of Transplantation supports the use of NRP. From a scientific perspective, NRP will increase organ use, reduce organ injury, and improve outcomes. To preserve public trust in organ donation, ethical issues need to be investigated, navigated, and discussed but are not insurmountable. NRP must be conducted within the confines of the UDDA. Finally, communication with donor families is paramount to ensure transparency. Further research is needed to assess families' information needs and communication strategies in a family-centered approach (Wall, et al., 2024).

The ASTS published Recommendations on best practices in donation after circulatory death organ procurement (ASTS/Croome, et al., 2022):

The Recommendations aim to provide guidance on contemporary issues surrounding donation after circulatory death (DCD) organ procurement in the United States. A work group was composed of members of the American Society of Transplant Surgeon Scientific Studies Committee and the Thoracic Organ Transplantation Committee. The following topics were identified by the group either as controversial or lacking standardization: pre-withdrawal preparation, definition of donor warm ischemia time, DCD surgical technique, combined thoracic and abdominal procurements, and normothermic regional perfusion. The proposed recommendations were classified on the basis of the grade of available evidence and the strength of the recommendation. This information should be valuable for transplant programs as well as for organ procurement organizations and donor hospitals as they develop robust DCD donor procurement protocols.

Summary of The American Society of Transplant Surgeons recommendations on best practice in donation after circulatory death organ procurement, specific to 'The use of NRP in the United States':

<b>The use of NRP in the United States</b>	<b>Grade of evidence</b>	<b>Strength of recommendation</b>
In many countries, normothermic regional perfusion (NRP) is considered an acceptable practice available to procure organs from DCD donors. When discussing NRP, it is important to specify if the procurement procedure being utilized involves abdominal normothermic regional perfusion (A-NRP) or thoracoabdominal normothermic regional perfusion (TA-NRP).	II-2 (Cohort or case-control analytic studies)	Strong (Strong, factors influencing the strength of recommendation included the quality of evidence, presumed patient-important outcomes, and costs.)
Terminology such as "reanimation," "resuscitation," and "extracorporeal membrane oxygenation" (ECMO) should be avoided when discussing NRP as these terms do not clearly reflect the	Expert Opinion III (Opinions of respected authorities,	Strong

process of organ recovery from a donor who has already been declared deceased due to hemodynamic arrest. In lieu, more specific and less emotionally laden terms such as “in situ tissue perfusion” or “dynamic in situ organ assessment” should be used.	descriptive epidemiology)	
Postmortem A-NRP and TA-NRP are safe and feasible in DCD organ procurement and may increase the organ utilization rate.	II-2	Weak (Variability in preferences and values or more uncertainty. The recommendation is made with less certainty, higher costs, or resource consumption)
The ASTS is supportive of exploring all options to increase organ donations. The ASTS strongly recommends that future guidelines for NRP protocols be developed, including ethical principles, viability assessment, acceptance criteria, and standardization of protocols (ASTS/Croome, et al., 2022).	Expert Opinion III	Strong

The ASTS published a Statement on Thoracoabdominal Normothermic Regional Perfusion Donation after Circulatory Determination of Death. It was drafted by the ASTS Ethics Advisory Committee, and approved by the ASTS Executive Committee on August 23, 2022. It includes but is not limited to the following:

Definition of the problem

Thoracoabdominal normothermic regional perfusion for donation after circulatory determination of death (TA-NRP DCD) utilizes oxygenated machine perfusion for the preservation of abdominal and thoracic organs rather than standard cold perfusion. After the donor has been pronounced and confirmed dead, and after waiting 2 to 5 minutes after the determination of circulatory death to ensure the decedent does not spontaneously resuscitate, the TA-NRP DCD procedure involves opening the chest, central cannulation, clamping of the brachiocephalic vessels and initiation of normothermic oxygenated perfusion to the organs that will be used for transplantation. The procurement proceeds in the same fashion as a brain-dead donor.

ASTS principles regarding the ethical acceptability of NRP-DCD procurement procedures

- The ethical acceptability of DCD donation is based on 3 fundamental principles: respect for autonomy, nonmaleficence and beneficence.
- Respect for autonomy requires that authorization is obtained for DCD donation as well as for any procedures done or medications administered for organ evaluation or preservation. In addition, the discussion about organ donation in the setting of DCD donation must occur after the decision to withdraw life-sustaining treatments has been made. Further, as is always the case, medical professionals attending to the patient and working with the family through end-of-life care and decisions must be separate and apart from those medical professionals who are part of the organ recovery or transplant team and process.



- Nonmaleficence requires that harm to the donor is avoided. First and foremost, this requires that potential DCD donors are provided with the same level of comfort care measures as individuals who undergo withdrawal of life-sustaining treatments without consideration for organ donation. Second, it requires that the organ procurement procedure commences after the donor is dead so that the procedure itself does not cause death (i.e., the dead donor rule).
- Death in DCD donation is determined by circulatory and respiratory criteria consistent with the legal definition of death in the Uniform Determination of Death Act, which has been adopted in all material respects by almost all states in the US. The UDDA states: "An individual who has sustained either (1) irreversible cessation of circulatory and respiratory functions, or (2) irreversible cessation of all functions of the entire brain, including the brain stem, is dead". DCD donors are declared dead in accordance with the UDDA and following accepted medical standards by a medical provider who is not a part of the organ procurement team and using the hospital's criteria for cardio-pulmonary death.
  - After the cessation of circulatory and respiratory function, a hands-off period is observed for irreversibility of circulatory death, during which there is an absence of auto-resuscitation and death is confirmed at the end of that period.
  - Circulatory death *occurs* when the heart and lungs have lost their ability to function within the organism and cannot contribute to the operation of the organism as a whole. Circulatory death is *confirmed* in a DCD donor after a hands-off period in which autoresuscitation does not occur. At that point, the donor is dead and the procurement team is allowed to proceed with organ procurement.
  - Ensuring that the donor is dead is essential to DCD donation because the procurement procedure occurs directly following confirmation of death.
- Beneficence requires that risks are minimized and benefits are maximized in medical procedures. Because DCD donors are dead at the time of donation, they do not benefit from the procedure, but there is benefit to family members who hope that their loved one can help as many others as possible through organ donation. Moreover, increasing the likelihood of benefit to organ transplant recipients is an element of beneficence considering the donor-recipient dyad.
- The ethical acceptability of TA-NRP DCD has been questioned because (1) the heart is re-perfused in the body, which some allege brings into question irreversibly, and (2) the brachiocephalic vessels are clamped before the initiation of NRP, which prevents reestablishment of flow to the brain but which some allege is a contributing cause to the death itself.
- The ASTS supports the ethical acceptability of TA-NRP DCD because this procedure meets the ethical baseline for DCD organ donation as follows: following a family's decision to cease all life-sustaining therapies for their loved one, authorization is obtained for TA-NRP donation as well as consent for ante-mortem interventions and medications in the same way as it is done for a standard DCD donor; nonmaleficence is fulfilled because the NRP procurement procedure does not start until the donor has been confirmed dead. Our analysis of the specific ethical concerns about TA-NRP DCD are as follows:
  - Perfusion of the organs in the body: This is not autoresuscitation or resuscitation of the donor. The donor is dead before the initiation of NRP. NRP is mechanically assisted regional perfusion and oxygenation of organs for transplantation.
  - Clamping the brachiocephalic vessels before the initiation of TA-NRP ensures that the brain is not reperfused. Circulatory death has already been

- determined under the UDDA and in accordance with accepted medical standards when the brachiocephalic vessels are clamped.
- Reperfusing the heart in the body on NRP is no different than restarting the heart outside of the body with machine perfusion. While this is optically different, in both cases, the heart is restarted with artificial machine assistance for the purpose of organ donation in a person who died intending to donate their organs. The heart would not continue to function within the donor without ventilatory support so it is functioning only with mechanical assistance for the purposes of organ donation.

The ASTS hopes to engage the medical and lay community in open, transparent dialogue about TA-NRP DCD donation to maintain trust in organ donation and demonstrate our commitment to the organ donors who make transplantation possible and save the lives of our patients (ASTS, 2022).

**American Society of Transplantation (AST):** The AST posted a Position Statement on Normothermic Regional Perfusion (NRP), August 24, 2022. The AST states:

- Innovation in modalities such as NRP that can increase organ use, reduce organ injury, and improve recipient outcomes is needed and should be utilized. Based on the current procedural, ethical and legal assessments on NRP in DCD donors, the AST supports the use of this technique and the development of associated strategies that promote its broader clinical implementation. This should be done in a transparent ethical framework that involves key stakeholders, including the critical care community, the donating public, and donor families.
- A clear communication plan regarding NRP for donor families and donor hospital personnel should be established for programs that are implementing NRP. Focus-group studies pertaining to how much detail should be shared with families regarding the organ recovery procedure should be conducted consistent with disclosure and authorization best practices already established by organ donation agencies in standard DCD cases.
- Critical ethical analysis of NRP-DCD should continue to ensure adherence to the principles of the dead donor rule and preserve public trust in donation.
- Legal clarification either through updates to the Uniform Determination of Death Act (UDDA) or other legal advisory or guidance should be developed to remove any perceived misalignment or legal barriers to NRP donation either as a clinical or a research protocol (AST, 2022).

### **Mechanical Preservation Machine - Literature Review**

There are unresolved issues surrounding organ preservation for transplantation. There is no uniform agreement on indications for the use of various machine perfusion devices. Inclusion/exclusion criteria in published studies vary by device, by donor status/donation criteria, and other factors. Numerous clinical trials are underway or recruiting on the Clinicaltrials.gov website. Long term health outcomes will help to identify the potential optimal cohort characteristics. Additionally, there is a lack of US federal government / OPTN guidance regarding the use of these devices in liver transplantation (Croome, et al., 2023; Sousa Da Silva, et al., 2022; Mugaanyi, et al., 2022; van Beekum, et al., 2021).

A Cochrane review and literature search was conducted (Tingle, et al., 2023) for clinical trials which compared perfusion machines used in liver transplantation. Researchers planned to include trials which compared perfusions machines with each other or compared with standard ice-box preservation. The primary outcomes were death, quality of life, and serious side effects (serious adverse events). Secondary outcomes included how long the transplanted liver survived, bile duct

(thin tubes that go from the liver to the small intestine) damage, and what proportion of the donated livers could be transplanted. The review includes studies published to January 10, 2023.

- Main results: Tingle et al. found six RCT with 854 transplant recipients from 1124 donated livers. No machine was shown to reduce death, and no trials looked at quality of life. Compared with the standard ice-box technique, cold machine perfusion improved the survival of the liver, reduced the number of serious adverse events, and reduced damage to the bile ducts. Warm machine perfusion with oxygen did not have these benefits. Warm machine perfusion appeared to increase the proportion of donated livers which could be transplanted, but more research is needed to understand why.
- What are the limitations of the evidence? Tingle et al. found a limited number of trials, and some were of mixed quality. The reported data were also insufficient for all planned analyses. None of the trials looked at a machine perfusion technique which is applied in the donor before the organs are removed (termed normothermic regional perfusion). The researchers identified 11 ongoing studies investigating machine perfusion technologies (Cochrane/Tingle, et al., 2023).

A multicenter randomized controlled trial (RCT) (International Randomized Trial to Evaluate the Effectiveness of the Portable Organ Care System Liver for Preserving and Assessing Donor Livers for Transplantation) (PROTECT) was conducted. The OCS Liver device from TransMedics® was used.

- The trial was designed to overcome the limitations of ischemic cold storage (ICS), limiting the period of ischemia and providing physiologic assessment of liver graft function. The PROTECT trial prespecified donor characteristics from donation after brainstem death (DBD) and donation after circulatory death (DCD) donors that are known to be more vulnerable to ICS associated damage. The PROTECT trial was designed to test for both noninferiority and superiority if noninferiority was met.
- The PROTECT trial objective was to compare the safety and the effectiveness of the OCS Liver vs ICS for Donors with at least 1 of the following characteristics: (1) 40 years of age or older; (2) expected total cross-clamp/cold ischemic time of 6 or more hours; (3) DCD donors if 55 years or younger; or (4) macrosteatotic livers ( $\leq 40\%$ ). Donor liver exclusion criteria included living donors, split livers, livers requiring accessory vessel reconstruction, or moderate to severe traumatic liver injury. Recipient exclusion criteria included younger than 18 years, acute or fulminant liver failure, prior solid organ or bone marrow transplant, chronic kidney failure, multiorgan transplant, ventilator dependence, or hemodynamic compromise.
- The primary effectiveness end point was the incidence of early allograft dysfunction (EAD) which was analyzed by calculating the sample proportion of patients meeting the primary effectiveness end point, as well as an exact (Clopper-Pearson) 95% CI for the corresponding population proportion.
- Per-protocol population consisted of 293 patients (151 in the OCS Liver group and 142 in the ICS group).
- The authors reported the primary effectiveness end point was met by a significant decrease in EAD (27 of 150 [18%] vs 44 of 141 [31%];  $P = .01$ ).
- Overall 12-month patient survival was 94.0% (142 of 151) for the OCS Liver group and 93.7% (133 of 142) for the ICS group (Markmann, et al., 2022).

A multicenter randomized controlled trial was conducted at ten European centers in six countries. The Liver Assist® (Organ Assist, now XVIVO) device was used.

- A total of 170 livers donated after brain death (DBD) were transplanted. Exclusion criteria included all partial or combined liver transplants, living donor or DCD liver transplantation,

cold ischemia times of more than 15 hours, and an acute or unexpected medical contraindication for LT.

- Conventionally cold stored (control group, N=85) was compared to cold stored AND subsequently treated by 1-2h hypothermic oxygenated perfusion (HOPE) before implantation (HOPE group, N=85). The primary endpoint was the occurrence of at least one post-transplant complication per patient, graded by the Clavien score of  $\geq$ III, within 1-year after LT.
- All patients completed the 1 year follow up, with the exception of deaths during this time (n=8). A total of 1190 complications were documented for all study patients during 1 year after LT with no patient lost to follow-up. The proportion of patients with at least one complication  $\geq$  Clavien IIIa did not significantly differ between groups with 54.1% (46/85) in the control group and 51.8% (44/85) in the HOPE Group ( $p=0.76$ ).
- There was also no significant difference in all pre-specified secondary endpoints, which focus on lab values, initial ICU- and hospital stay, and survival. However, many patients developed more than one major complication within one year follow-up. The extent of post-transplant morbidity was only recognized by the frequency and the severity grade of complications, with a 74% lower number of liver related Clavien  $\geq$ IIIb complications in the HOPE-arm, compared to the control group.
- The authors noted there was no relevant clinical difference between the two groups in the severity of serious adverse events and that the post hoc findings of this trial should be further validated in future studies (Schlegel, et al., 2023).

A multicenter randomized controlled trial evaluated normothermic machine perfusion (NMP). In the static cold storage (SCS) arm, the organ retrieval, storage and the transplant were conducted according to standard practice. In the NMP arm, following removal from the donor, the liver was attached to the OrganOx metra NMP device.

- Inclusion criteria for donors and recipients were deliberately broad to represent the full spectrum of clinical practice. Whole livers from brainstem death donors (DBD) and declared dead by cardiovascular criteria (DCD) donors at least 16 years of age were eligible. Recipients were eligible provided they were at least 18 years old and listed for a liver-only transplant, excluding those with fulminant liver failure.
- The primary endpoint was defined as the difference between the two treatment arms in the peak level of serum aspartate transaminase (AST) within seven days after transplant.
- Following organ retrieval, a markedly different discard rate between the two trial arms resulted in 100 static cold storage (SCS) and 120 NMP livers were available for primary outcome reporting, with 101 SCS and 121 NMP livers available for secondary outcome analysis. This discrepancy in group size reduced the study power to 89.7%.
- The authors reported peak AST during the first 7 days after transplant was reduced by 49.4% in the NMP group compared to static cold storage (SCS) when adjusted by center and donor type ( $P < 0.001$ ). Data to assess early allograft dysfunction (EAD) rates were available in 216 recipients: the odds of developing EAD in the NMP arm (12 out of 119) were 74% lower than the SCS arm (29 out of 97;  $P < 0.001$ ). There was no significant difference in bile duct complications, graft survival or survival of the patient (Nasralla, et al., 2018).

A multicenter randomized controlled trial DHOPE-DCD (Dual Hypothermic Oxygenated Perfusion of DCD Liver Grafts in Preventing Nonanastomotic Biliary Strictures after Transplantation) was conducted. The Liver Assist device (Organ Assist from XVIVO) was used.

- Patients 18 years of age or older who were undergoing liver-only transplantation with a graft from a donor after circulatory death (in controlled circumstances) were eligible for inclusion. Patients were excluded if the body weight of the donor was less than 40 kg or if the donor was positive for the human immunodeficiency virus or hepatitis B or C virus.

Patients were also excluded if they were undergoing transplantation for fulminant liver failure or for primary nonfunction after a previous transplantation, were incapable of providing informed consent, were positive for the human immunodeficiency virus, or had a contraindication to undergoing magnetic resonance cholangiography. The donor liver had been deemed to be suitable and had been accepted by the transplantation surgeon for a recipient after circulatory death.

- The primary end point was the incidence of symptomatic nonanastomotic biliary strictures at 6 months after transplantation.
- The reporting study population included 78 patients in the machine-perfusion group and 78 patients in the control group (received a liver after static cold storage only).
- The authors reported nonanastomotic biliary strictures occurred in 6% of the patients in the machine-perfusion group and in 18% of those in the control group ( $P = 0.03$ ). There were no relevant differences between the two groups in the use of renal-replacement therapy, in the durations of stay in the intensive care unit or hospital, or in graft and patient survival at 1 year (van Rijn, et al., 2021).

An open-label, randomized trial was conducted in Italy. The Vitasmart (Bridge to Life) machine was used.

- A total of 110 patients underwent extended criteria donors (ECD) grafts. Donors were considered eligible for the trial if they met the United Network for Organ Sharing (UNOS) criteria for ECD. Exclusion criteria included donor age < 18 years, split-liver recipients, LT for acute liver failure, and the development of intraoperative surgical complications before the organ implantation. Donors after circulatory death (DCD) were also excluded due to the Italian law.
- Patients were randomized to receive a liver after Hypothermic Oxygenated Perfusion (HOPE) or after static cold storage (SCS) alone.
- Median follow-up period was 473 days (15.76 mo). Early allograft dysfunction occurred in seven of the 55 patients (13%) in the HOPE group and in 19 of the 55 patients (35%) in the SCS group ( $p = .007$ ). Post hoc power analysis was performed which showed the study to be slightly underpowered (110 patients enrolled versus a total of 118 required to achieve 80% power) (Ravaioli, et al., 2022).

Czigany et al. (2021) conducted a multicenter RCT assessing peak serum alanine aminotransferase (ALT) during the first seven days following LT as the primary endpoint. End-ischemic HOPE (Liver Assist; Organ Assist) was applied through the portal vein for a minimum of 1 hour before implantation.

- Secondary endpoints included incidence of postoperative complications [Clavien-Dindo classification (CD), Comprehensive Complication Index (CCI)], length of intensive care (ICU) and hospital-stay, and incidence of early allograft dysfunction (EAD).
- A total of 46 patients undergoing extended criteria donation (ECD) liver transplantation (LT) from donation after brain death (DBD) were included. Half were randomized to hypothermic oxygenated machine perfusion (HOPE) ( $N=23$ ) and half to static cold storage ( $N=23$ ).
- All 46 patients were included in the final analysis. The authors concluded that end-ischemic treatment with HOPE led to a significant decrease in the primary endpoint, serum peak ALT, indicating a reduced allograft injury after reperfusion. HOPE resulted in a 47% decrease in serum peak ALT [ $P=0.030$ ]. The authors noted that lower peak levels of ALT after HOPE also correlate with superior post-transplant outcomes; there was a significant reduction in 90-day complications [ $P=0.036$ ]. The rate of major postoperative complications (CD grade  $\geq 3$ ) after LT was 44% in HOPE treated allografts versus 74% in the SCS arm.

Mugaanyi et al. (2022) conducted a meta-analysis. The PubMed, Web of Science and Scopus databases were queried for studies reporting on normothermic and hypothermic machine perfusion in liver transplantation through September 2022.

- A total of 10 studies with 1104 liver transplant recipients were analyzed (504 machine-perfused livers and 600 static cold-storage livers). Of the 504 perfused livers, 371 were NMP and 133 were HOPE. In one study, HOPE was combined with normothermic regional perfusion (NRP).
- The authors reported that machine perfusion is associated with more favorable postoperative outcomes. However, there appears to be some difference in the postoperative outcomes of HOPE/D-HOPE vs. SCS and those of NMP vs. SCS. In a pooled analysis of machine perfusion (NMP and HOPE/D HOPE) vs. SCS, graft survival was significantly better in the machine perfusion group. However, the studies were significantly heterogeneous.
- HOPE had a significantly lower incidence of biliary complications than SCS. However, the difference was not significant for NPM vs. SCS, and yet again, the studies were heterogeneous. The authors concluded that HOPE/D-HOPE and NMP are promising alternatives to SCS for donor liver preservation.

## Medicare Coverage Determinations

	Contractor	Determination Name/Number	Revision Effective Date
NCD		Adult Liver Transplantation (260.1) Pediatric Liver Transplantation (260.2)	9/04/2012 9/01/1991
LCD		No Determination found	

Note: Please review the current Medicare Policy for the most up-to-date information.  
(NCD = National Coverage Determination; LCD = Local Coverage Determination)

## Coding Information

### Notes:

1. This list of codes may not be all-inclusive since the American Medical Association (AMA) and Centers for Medicare & Medicaid Services (CMS) code updates may occur more frequently than policy updates.
2. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT®* Codes	Description
47133	Donor hepatectomy (including cold preservation), from cadaver donor
47135	Liver allotransplantation, orthotopic, partial or whole, from cadaver or living donor, any age
47140	Donor hepatectomy (including cold preservation), from living donor; left lateral segment only (segments II and III)
47141	Donor hepatectomy (including cold preservation), from living donor; total left lobectomy (segments II, III and IV)
47142	Donor hepatectomy (including cold preservation), from living donor; total right lobectomy (segments V, VI, VII and VIII)

<b>CPT®*</b> <b>Codes</b>	<b>Description</b>
47143	Backbench standard preparation of cadaver donor whole liver graft prior to allotransplantation, including cholecystectomy, if necessary, and dissection and removal of surrounding soft tissues to prepare the vena cava, portal vein, hepatic artery, and common bile duct for implantation; without trisegment or lobe split
47144	Backbench standard preparation of cadaver donor whole liver graft prior to allotransplantation, including cholecystectomy, if necessary, and dissection and removal of surrounding soft tissues to prepare the vena cava, portal vein, hepatic artery, and common bile duct for implantation; with trisegment split of whole liver graft into 2 partial liver grafts (ie, left lateral segment [segments II and III] and right trisegment [segments I and IV through VIII])
47145	Backbench standard preparation of cadaver donor whole liver graft prior to allotransplantation, including cholecystectomy, if necessary, and dissection and removal of surrounding soft tissues to prepare the vena cava, portal vein, hepatic artery, and common bile duct for implantation; with lobe split of whole liver graft into 2 partial liver grafts (ie, left lobe [segments II, III, and IV] and right lobe [segments I and V through VIII])
47146	Backbench reconstruction of cadaver or living donor liver graft prior to allotransplantation; venous anastomosis, each
47147	Backbench reconstruction of cadaver or living donor liver graft prior to allotransplantation; arterial anastomosis, each

<b>HCPCS</b> <b>Codes</b>	<b>Description</b>
S2152	Solid organ(s), complete or segmental, single organ or combination of organs; deceased or living donor(s), procurement, transplantation, and related complications; including: drugs; supplies; hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services, and the number of days of pre- and post-transplant care in the global definition

**Considered Not Medically Necessary when used to report a mechanical preservation machine for use with liver transplantation:**

<b>HCPCS</b> <b>Codes</b>	<b>Description</b>
E1399	Durable medical equipment, miscellaneous
0894T	Cannulation of the liver allograft in preparation for connection to the normothermic perfusion device and decannulation of the liver allograft following normothermic perfusion (Code effective 07/01/2024)

**\*Current Procedural Terminology (CPT®) ©2023 American Medical Association: Chicago, IL.**

## References

1. American Association for the Study of Liver Disease. Practice Guidelines. (Martin 2014; Squires 2014) Accessed Feb 2024. Available at URL address: <https://www.aasld.org/practice-guidelines>

2. American College of Physicians. Ethics, Determination of Death, and Organ Transplantation in Normothermic Regional Perfusion (NRP) with Controlled Donation after Circulatory Death (cDCD): American College of Physicians Statement of Concern. Approved by the Board of Regents on April 17, 2021. Accessed Feb 2024. Available at URL address:  
[https://assets.acponline.org/acp\\_policy/policies/ethics\\_determination\\_of\\_death\\_and\\_organ\\_transplantation\\_in\\_nrp\\_2021.pdf](https://assets.acponline.org/acp_policy/policies/ethics_determination_of_death_and_organ_transplantation_in_nrp_2021.pdf)  
<https://www.acponline.org/clinical-information/medical-ethics-and-professionalism/medical-ethics-issues-position-papers-resources/individual-position-papers>
3. American Society of Transplantation (AST). GUIDELINES AND OPINIONS. Liver/Intestines. Accessed Feb 2024. Available at URL address:  
<https://www.myast.org/education/guidelines-and-opinions#>
4. American Society of Transplantation (AST). Key Position Statements. Accessed Feb 2024. Available at URL address:  
<https://www.myast.org/public-policy/key-position-statements/key-position-statements>
5. American Society of Transplant Surgeons (ASTS). Position Statements. Accessed March 2024. Available at URL address: <https://asts.org/advocacy/position-statements> (Wall, 2024; Croome, 2022)
6. Bari K, Sharma P. Optimizing the Selection of Patients for Simultaneous Liver-Kidney Transplant. Clin Liver Dis. 2021 Feb;25(1):89-102.
7. Bonney GK, Chew CA, Lodge P, Hubbard J, Halazun KJ, Trunecka P, et al. Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. Lancet Gastroenterol Hepatol. 2021 Nov;6(11):933-946. Erratum in: Lancet Gastroenterol Hepatol. 2021 Nov;6(11):e7.
8. Bridge to Life, Ltd. VitaSmart™ Liver Machine Perfusion System. Accessed February 2024. Available at URL address:  
<https://bridgetolife.eu/bridge-to-life-ltd-receives-investigational-device-exemption-approval-from-the-fda/>  
<https://www.prnewswire.com/news-releases/bridge-to-life-ltd-receives-investigational-device-exemption-approval-from-the-fda-301444018.html>
9. <https://www.prnewswire.com/news-releases/advancing-transplantation-technologies-bridge-to-hope-trial-demonstrates-promising-findings-with-hypothermic-oxygenated-perfusion-301875448.html>
10. Cambridge WA, Fairfield C, Powell JJ, Harrison EM, Søreide K, et al. Meta-analysis and Meta-regression of Survival After Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma. Ann Surg. 2021 Feb 1;273(2):240-250.
11. Centers for Medicare and Medicaid Services (CMS). National Coverage Determination (NCD) Adult LIVER TRANSPLANTATION Adult Liver Transplantation (260.1). 9/4/2012. Accessed Feb 2024. Available at URL address: <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCID=70&ncdver=3&SearchType=Advanced&CoverageSelection=Both&NCSelection=NCA%7cCAL%7cNCD%7cMEDCAC%7cTA%7cMCD&ArticleType=SAD%7cEd&PolicyType=Both&s=All&KeyWord=LIVER+TRANSPLANTATION&KeyWordLookUp=Title&KeyWordSearchType=Exact&kq=true&bc=IAAAACAAAA&>
12. Centers for Medicare and Medicaid Services (CMS). National Coverage Determination (NCD) Pediatric LIVER TRANSPLANTATION (260.2). 9/01/1991. Accessed Feb 2024. Available at



URL address: <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=71&ncdver=1&SearchType=Advanced&CoverageSelection=Both&NCSelection=NCA%7cCAL%7cNCD%7cMEDCAC%7cTA%7cMCD&ArticleType=SAD%7cEd&PolicyType=Both&s=All&KeyWord=LIVER+TRANSPLANTATION&KeyWordLookup=Title&KeyWordSearchType=Exact&kq=true&bc=IAAAACAAAA&>

13. Chadban SJ, Ahn C, Axelrod DA, Foster BJ, Kasiske BL, et al. KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. *Transplantation*. 2020 Apr;104(4S1 Suppl 1):S11-S103. Accessed Feb 2024. Available at URL address: <https://kdigo.org/guidelines/transplant-candidate/>
14. Croome KP. Introducing Machine Perfusion into Routine Clinical Practice for Liver Transplantation in the United States: The Moment Has Finally Come. *J Clin Med*. 2023 Jan 23;12(3):909.
15. Croome KP, Barbas AS, Whitson B, Zarrinpar A, American Society of Transplant Surgeons Scientific Studies Committee, et al. American Society of Transplant Surgeons recommendations on best practices in donation after circulatory death organ procurement. *Am J Transplant*. 2022 Dec 23:S1600-6135(22)29300-9. doi: 10.1016/j.ajt.2022.10.009. Epub ahead of print. PMID: 36695685.
16. Czigan Z, Pratschke J, Froněk J, Guba M, Schöning W, Raptis DA, et al. Hypothermic Oxygenated Machine Perfusion Reduces Early Allograft Injury and Improves Post-transplant Outcomes in Extended Criteria Donation Liver Transplantation From Donation After Brain Death: Results From a Multicenter Randomized Controlled Trial (HOPE ECD-DBD). *Ann Surg*. 2021 Nov 1;274(5):705-712.
17. Dueland S, Syversveen T, Solheim JM, Solberg S, Grut H, et al. Survival Following Liver Transplantation for Patients With Nonresectable Liver-only Colorectal Metastases. *Ann Surg*. 2020 Feb;271(2):212-218.(SECA II)
18. Dueland S, Smedman TM, Syversveen T, Grut H, Hagness M, Line PD. Long-Term Survival, Prognostic Factors, and Selection of Patients With Colorectal Cancer for Liver Transplant: A Nonrandomized Controlled Trial. *JAMA Surg*. 2023 Sep 1;158(9):e232932.
19. Goyes D, Nsubuga JP, Medina-Morales E, Patwardhan V, Bonder A. New OPTN Simultaneous Liver-Kidney Transplant (SLKT) Policy Improves Racial and Ethnic Disparities. *J Clin Med*. 2020 Dec 1;9(12):3901.
20. Hagness M, Foss A, Line PD, Scholz T, Jørgensen PF, Fosby B, et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. *Ann Surg*. 2013 May;257(5):800-6. (SECA I)
21. Hibi T, Rela M, Eason JD, Line PD, Fung J, Sakamoto S, et al. Liver Transplantation for Colorectal and Neuroendocrine Liver Metastases and Hepatoblastoma. Working Group Report From the International Liver Transplantation Society (ILTS) Transplant Oncology Consensus Conference. *Transplantation*. 2020 Jun;104(6):1131-1135.
22. Huang DC, Fricker ZP, Alqahtani S, Tamim H, Saberi B, Bonder A. The influence of equitable access policies and socioeconomic factors on post-liver transplant survival. *EClinicalMedicine*. 2021 Sep 16;41:101137.

23. Jay CL, Washburn WK, Rogers J, Harriman D, Heimbach J, Stratta RJ. Difference in Survival in Early Kidney after Liver Transplantation Compared with Simultaneous Liver-Kidney Transplantation: Evaluating the Potential of the "Safety Net". *J Am Coll Surg*. 2020;230(4):463-473.
24. Lebeck Lee CM, Ziogas IA, Agarwal R, Alexopoulos SP, Ciombor KK, Matsuoka LK, Brown DB, Eng C. A contemporary systematic review on liver transplantation for unresectable liver metastases of colorectal cancer. *Cancer*. 2022 Jun 15;128(12):2243-2257.
25. Mansour MM, Fard D, Basida SD, Obeidat AE, Darweesh M, Mahfouz R, Ahmad A. Disparities in Social Determinants of Health Among Patients Receiving Liver Transplant: Analysis of the National Inpatient Sample From 2016 to 2019. *Cureus*. 2022 Jul 5;14(7):e26567.
26. Markmann JF, Abouljoud MS, Ghobrial RM, Bhati CS, Pelletier SJ, et al. Impact of Portable Normothermic Blood-Based Machine Perfusion on Outcomes of Liver Transplant: The OCS Liver PROTECT Randomized Clinical Trial. *JAMA Surg*. 2022 Mar 1;157(3):189-198.
27. Martin P, DiMartini A, Feng S, Brown R Jr, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. *Hepatology*. 2014 Mar;59(3):1144-65.
28. Mazzaferro V, Citterio D, Bhoori S, Bongini M, Miceli R, et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. *Lancet Oncol*. 2020 Jul;21(7):947-956. Erratum in: *Lancet Oncol*. 2020 Aug;21(8):e373.
29. Moris D, Kostakis ID, Machairas N, Prodromidou A, Tsilimigras DI, et al. Comparison between liver transplantation and resection for hilar cholangiocarcinoma: A systematic review and meta-analysis. *PLoS One*. 2019 Jul 31;14(7):e0220527. eCollection 2019.
30. Mugaanyi J, Dai L, Lu C, Mao S, Huang J, Lu C. A Meta-Analysis and Systematic Review of Normothermic and Hypothermic Machine Perfusion in Liver Transplantation. *J Clin Med*. 2022 Dec 28;12(1):235.
31. Nasralla D, Coussios CC, Mergental H, Akhtar MZ, Butler AJ, Consortium for Organ Preservation in Europe, et al. A randomized trial of normothermic preservation in liver transplantation. *Nature*. 2018 May;557(7703):50-56.
32. National Cancer Institute. Adult primary liver cancer treatment (PDQ®). Updated: 8/22/23. Accessed Feb 2024. Available at URL address: <https://www.cancer.gov/types/liver/hp/adult-liver-treatment-pdq>
33. National Cancer Institute. Childhood liver cancer treatment (PDQ®). Updated: 12/15/23. Accessed Feb 2024. Available at URL address: <https://www.cancer.gov/types/liver/hp/child-liver-treatment-pdq>
34. National Cancer Institute. Adult Colon Cancer Treatment (PDQ®). Updated 1/23/24. Accessed Feb 2024. Available at URL address: <https://www.cancer.gov/types/colorectal/hp/colon-treatment-pdq>
35. National Comprehensive Cancer Network® (NCCN). NCCN GUIDELINES™ Clinical Guidelines in Oncology™. © National Comprehensive Cancer Network, Inc. 2024, All Rights Reserved.

Clinical practice guidelines in oncology: Accessed Mar 2024. Available at URL address: [https://www.nccn.org/professionals/physician\\_gls/pdf/](https://www.nccn.org/professionals/physician_gls/pdf/)

36. Nephew LD, Serper M. Racial, Gender, and Socioeconomic Disparities in Liver Transplantation. *Liver Transpl.* 2021 Jun;27(6):900-912.
37. Olumba FC, Zhou F, Park Y, Chapman WC; and the RESTORE Investigators Group. Normothermic Machine Perfusion for Declined Livers: A Strategy to Rescue Marginal Livers for Transplantation. *J Am Coll Surg.* 2023 Apr 1;236(4):614-625. NCT04483102.
38. Organ Procurement and Transplantation Network. Policies & bylaws. A closer look. Liver. Accessed Feb 2024. Available at URL address: <https://optn.transplant.hrsa.gov/policies-bylaws/a-closer-look/liver/>
39. Organ Procurement and Transplantation Network. Governance. Policies. Policy 9: Allocation of Livers and Liver-Intestines. Last updated 03/19/2024. Accessed Mar 2024. Available at URL address: <https://optn.transplant.hrsa.gov/policies-bylaws/policies/>
40. Organ Procurement and Transplantation Network. Resources, Allocation Calculators. Page not dated. (MELD/PELD) Accessed Feb 2024. Available at URL address: <https://optn.transplant.hrsa.gov/resources/allocation-calculators/>
41. OrganOx metra®. Accessed Feb 2024. Available at URL address: <https://www.organox.com/evidence>
42. Panayotova GG, Lunsford KE, Quillin RC 3rd, Rana A, Agopian VG, et al. Portable hypothermic oxygenated machine perfusion for organ preservation in liver transplantation (PILOT™): A randomized, open-label, clinical trial. *Hepatology.* 2023 Dec 13. doi: 10.1097/HEP.0000000000000715. Epub ahead of print. PMID: 38090880. (NCT03484455)
43. Paragonix LIVERguard™ Donor Liver Preservation System. Accessed February 2024. Available at URL address: <https://paragonixtechnologies.com/products/liverguard-system/>  
<https://www.paragonixtechnologies.com/indications-of-use>  
<https://www.paragonixtechnologies.com/clinical-publications> (no liver publications)
44. Ravaioli M, Germinario G, Dajti G, Sessa M, Vasuri F, Siniscalchi A, et al. Hypothermic oxygenated perfusion in extended criteria donor liver transplantation-A randomized clinical trial. *Am J Transplant.* 2022 Oct;22(10):2401-2408.
45. Rayar M, Beaurepaire JM, Bajoux E, Hamonic S, Renard T, et al. Hypothermic Oxygenated Perfusion Improves Extended Criteria Donor Liver Graft Function and Reduces Duration of Hospitalization Without Extra Cost: The PERPHO Study. *Liver Transpl.* 2021 Feb;27(3):349-362. NCT03376074
46. Robinson TJ, Cummins K, Tsung A. Liver Transplantation for Unresectable Colorectal Liver Metastasis: Perspective and Review of Current Literature. *Curr Oncol.* 2024 Feb 16;31(2):1079-1090.
47. Sasaki K, Ruffolo LI, Kim MH, Fujiki M, Hashimoto K, Imaoka Y, Melcher ML, Aucejo FN, Tomiyama K, Hernandez-Alejandro R. The Current State of Liver Transplantation for Colorectal Liver Metastases in the United States: A Call for Standardized Reporting. *Ann Surg Oncol.* 2023 May;30(5):2769-2777.

48. Schepers EJ, Hartman SJ, Whitrock JN, Quillin RC 3rd. Liver Transplantation for Colorectal Liver Metastases. *Surg Clin North Am.* 2024 Feb;104(1):227-242.
49. Schlegel A, Mueller M, Muller X, Eden J, Panconesi R, von Felten S, et al. A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation. *J Hepatol.* 2023 Jan 18:S0168-8278(23)00012-0. Epub ahead of print.
50. Singal AK, Ong S, Satapathy SK, Kamath PS, Wiesner RH. Simultaneous liver kidney transplantation. *Transpl Int.* 2019;32(4):343-352.
51. Smedman TM, Line PD, Hagness M, Syversveen T, Grut H, Dueland S. Liver transplantation for unresectable colorectal liver metastases in patients and donors with extended criteria (SECA-II arm D study). *BJS Open.* 2020 Jun;4(3):467-477. (SECA Arm D)
52. Sousa Da Silva RX, Weber A, Dutkowski P, Clavien PA. Machine perfusion in liver transplantation. *Hepatology.* 2022 Nov;76(5):1531-1549.
53. Squires RH, Ng V, Romero R, Ekong U, Hardikar W, Emre S, et al. Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. *Hepatology.* 2014 Jul;60(1):362-98. Accessed Feb 2024. Available at URL address: <https://www.aasld.org/practice-guidelines>
54. Tingle SJ, Dobbins JJ, Thompson ER, Figueiredo RS, Mahendran B, et al. Machine perfusion in liver transplantation. *Cochrane Database of Systematic Reviews 2023, Issue 9.* Art. No.: CD014685
55. TransMedics. OCS Liver. Accessed Feb 2024. Available at URL address: <https://www.transmedics.com/publications/> (no liver studies listed)
56. U.S. Department of Health and Human Services. Scientific Registry of Transplant Recipients (SRTR). Accessed Feb 2024. Available at URL address: [https://srtr.transplant.hrsa.gov/annual\\_reports/Default.aspx](https://srtr.transplant.hrsa.gov/annual_reports/Default.aspx)
57. U.S. Food and Drug Administration. Center for Devices and Radiological Health (CDRH). PMA Approval. Organ Care System (OCS™) Liver (TransMedics). September 28, 2021 (P200031). Accessed Feb 2024. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P200031>  
[https://www.accessdata.fda.gov/cdrh\\_docs/pdf20/P200031A.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200031A.pdf)
58. U.S. Food and Drug Administration. Center for Devices and Radiological Health (CDRH). PMA Approval. OrganOx metra® System. December 9, 2021 (P200035). Accessed Feb 2024. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P200035>  
[https://www.accessdata.fda.gov/cdrh\\_docs/pdf20/P200035A.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200035A.pdf)  
[https://www.accessdata.fda.gov/cdrh\\_docs/pdf20/P200035B.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200035B.pdf)
59. United States Food and Drug Administration (FDA). 510(k) summary. Center for Devices and Radiological Health (CDRH). K201048. SherpaPak Pediatric Liver Transport System (Paragonix Technologies) July 2, 2020. Accessed Feb 2024. Available at URL address:

[https://www.accessdata.fda.gov/cdrh\\_docs/pdf20/K201048.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf20/K201048.pdf) (not mechanical perfusion device, cold storage transport only)

60. van Beekum CJ, Vilz TO, Glowka TR, von Websky MW, Kalff JC, Manekeller S. Normothermic Machine Perfusion (NMP) of the Liver - Current Status and Future Perspectives. *Ann Transplant.* 2021 Aug 24;26:e931664.
61. van Rijn R, Schurink IJ, de Vries Y, van den Berg AP, Cortes Cerisuelo M, DHOPE-DCD Trial Investigators, et al. Hypothermic Machine Perfusion in Liver Transplantation - A Randomized Trial. *N Engl J Med.* 2021 Apr 15;384(15):1391-1401.
62. Wall AE, Adams BL, Brubaker A, Chang CWJ, Croome KP, et al. The American Society of Transplant Surgeons Consensus Statement on Normothermic Regional Perfusion. *Transplantation.* 2024 Feb 1;108(2):312-318.
63. Warren C, Carpenter AM, Neal D, Andreoni K, Sarosi G, Zarrinpar A. Racial Disparity in Liver Transplantation Listing. *J Am Coll Surg.* 2021 Apr;232(4):526-534.
64. XVIVO. Liver Assist. Accessed Feb 2024. Available at URL address:  
[https://www.xvivoperfusion.com/mfn\\_news/xvivo-granted-breakthrough-device-designation-from-the-fda-for-the-liver-assist-device/](https://www.xvivoperfusion.com/mfn_news/xvivo-granted-breakthrough-device-designation-from-the-fda-for-the-liver-assist-device/)  
<https://www.xvivoperfusion.com/products/>  
[https://www.organ-assist.nl/wp-content/uploads/2021/08/Liver\\_assist\\_TD-11\\_Brochure\\_LiA.08.pdf](https://www.organ-assist.nl/wp-content/uploads/2021/08/Liver_assist_TD-11_Brochure_LiA.08.pdf)  
<https://www.organ-assist.nl/evidence-based-machine-perfusion-technology/>
65. Yilma M, Kim NJ, Shui AM, Tana M, Landis C, Chen A, Bangaru S, Mehta N, Zhou K. Factors Associated With Liver Transplant Referral Among Patients With Cirrhosis at Multiple Safety-Net Hospitals. *JAMA Netw Open.* 2023 Jun 1;6(6):e2317549

## Revision Details

Type of Revision	Summary of Changes	Date
Annual review	<ul style="list-style-type: none"><li>• Revised policy statement for liver transplantation</li><li>• Revised policy statement for mechanical preservation machines</li></ul>	5/15/2024

---

“Cigna Companies” refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna Group.